NDAINHALATIONLIQUIDPriority Review
Approved
Dec 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
Priority Review
FORANE (isoflurane) by Baxter is 12. First approved in 1979.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FORANE (isoflurane) is a volatile general anesthetic administered via inhalation for rapid induction and maintenance of anesthesia during surgical procedures. It works by depressing the central nervous system and producing profound respiratory depression while maintaining stable cardiac rhythm and blood pressure relative to depth of anesthesia. Isoflurane is used across all surgical settings where general anesthesia is required.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), indicating consolidation of commercial operations and reduced headcount expansion.
Mechanism of Action
12.2 Pharmacodynamics Induction of and recovery from isoflurane anesthesia are rapid. Isoflurane has a mild pungency which limits the rate of induction, although excessive salivation or tracheobronchial secretions do not appear to be stimulated. Pharyngeal and laryngeal reflexes are readily…
Worked on FORANE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.